Related Experiment Video

Updated: Jul 29, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome

Shuangcui Wang1, Yuli Wang2, Yun Deng2

  • 1Oncology Department, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Frontiers in Pharmacology
|May 22, 2023
PubMed

Insights

Cardiorenal syndrome (CRS) involves heart and kidney dysfunction. Sacubitril/valsartan, targeting both renin-angiotensin-aldosterone system (RAAS) and natriuretic peptide (NP) systems, shows promise for treating CRS, though further research is needed.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Cardiorenal syndrome (CRS) is a complex condition with increasing incidence and mortality.
  • Current treatments for CRS are limited, with drugs targeting only the renin-angiotensin-aldosterone system (RAAS) or natriuretic peptide (NP) systems proving ineffective.
  • Sacubitril/valsartan simultaneously modulates both RAAS and NP systems.

Purpose of the Study:

  • To summarize the pathophysiological mechanisms of CRS.
  • To review the preliminary clinical application effects of sacubitril/valsartan in CRS prevention and treatment.
  • To provide a pharmacological basis for using sacubitril/valsartan in CRS management.

Main Methods:

  • Literature review focusing on RAAS and NP systems in CRS.
  • Analysis of existing research on sacubitril/valsartan's effects on cardiovascular and renal function.
  • Examination of recent studies, including animal models combining levosimendan and sacubitril/valsartan.

Main Results:

  • Sacubitril/valsartan simultaneously regulates RAAS and NP systems, key pathways in CRS.
  • Recent research indicates potential cardioprotective and renoprotective effects of combined levosimendan and sacubitril/valsartan in rats.
  • Clinical data on sacubitril/valsartan specifically for CRS treatment remains inconclusive.

Conclusions:

  • Sacubitril/valsartan presents a potential therapeutic strategy for CRS due to its dual-action mechanism.
  • Further clinical studies are warranted to confirm the efficacy and safety of sacubitril/valsartan in treating cardiorenal syndrome.
  • Understanding RAAS and NP biomarkers is crucial for advancing CRS pharmacotherapy.

Keywords:
NPSRAAScardiorenal syndromeresearch progresssacubitril/valsartan

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research03:13

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research

Published on: November 3, 2023

2.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
18
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
19
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
57
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
717